您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Astragaloside A(Astramembrannin I Astragalin A)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Astragaloside A(Astramembrannin I Astragalin A)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Astragaloside A(Astramembrannin I Astragalin A)图片
CAS NO:83207-58-3
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)784.97
FormulaC41H68O14
CAS No.83207-58-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (127.4 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other infoSMILES: O[C@H]1[C@H](O)[C@@H](CO)O[C@](O[C@H]2C[C@]([C@@](C[C@H](O)[C@]3([H])[C@@]4(C)O[C@@H](C(C)(O)C)CC4)(C)[C@]3(C)CC5)([H])[C@]56[C@]7(C6)[C@]2([H])C(C)(C)[C@@H](O[C@]8([H])OC[C@@H](O)[C@H](O)[C@H]8O)CC7)([H])[C@@H]1O
InChi Code: InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24
InChi Key: QMNWISYXSJWHRY-AUJDEUPOSA-N
Chemical Name: 20,24R-epoxy-16β,25-dihydroxy-3β-(β-D-xylopyranosyloxy)-9,19-cyclolanostan-6α-yl-β-D-glucopyranoside
SynonymsAS-A; AST-A; Astramembrannin I; Astragalin A
实验参考方法
In Vitro

In vitro activity: Astragaloside IV improves post-ischemic heart function and ameliorated reperfusion arrhythmias accompanied by a significant increase in myocardial antioxidative enzyme superoxide dismutase activity in rat hearts in vitro. While, Astragaloside IV's protective effect on heart function can be partially abrogated by the nitric oxide synthase inhibitor, Nomega-nitro-L-arginine methyl ester.


Kinase Assay: AS-IV treatment also activates JAK2/STAT3 and ERK1/2 signaling pathways, and up-regulates endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production


Cell Assay: Astragaloside IV (2-40 μM) dose-dependently decreased TGF-β-induced a-SMA, fibronectin, CTGF, collagen I and III expression, up-regulated Smad7, but decreased p-Smad2 and p-Smad3 expression in NRK-49F cells [2]. Moreover, Astragaloside IV prevented tubular epithelial apoptosis partially through inhibiting MAPK pathway activity, thereby ameliorating renal fibrosis.

In VivoAstragaloside IV significantly reduces infarct size in dogs subjected to coronary ligation in vivo. Astragaloside IV attenuates isoproterenol-induced subendocardial necrosis, serum lactate dehydrogenase and creatine kinase activation, and lipid oxide product malondialdehyde formation in rats. It also reduces sarcoplasmic reticulum Ca(2+)-uptake ability and Ca(2+)-ATPase (SERCA2a) activity as well as SERCA2a mRNA expression in myocardial injury rats.
Animal modelAstragaloside IV (5 and 10 mg/kg/day, intraperitoneal injection) reduced serum lactate dehydrogenase and creatine kinase enzyme levels and attenuated this reduction in the Ca2+-ATPase activity in rats. Astragaloside IV (3.33, 10, and 33 mg/kg, intraperitoneal injection) treatment attenuated renal damage and improved renal function through inhibiting TGF-β/Smad signaling pathway in a dose-dependent manner in unilateral ureteral obstruction kidneys.
Formulation & Dosage 5 and 10 mg/kg; 3.33, 10, and 33 mg/kg, intraperitoneal injection
ReferencesPlanta Med. 2006 Jan;72(1):4-8; Eur J Pharmacol. 2007 Jul 30;568(1-3):203-12.